Agenus(AGEN.US)

Last Updated 19:00:00 ET
longbridge loading

Agenus Announces Publication of Phase 1b Botensilimab and Balstilimab Data in Post-Immunotherapy Hepatocellular Carcinoma in Liver Cancer | AGEN Stock News

StockTitan·
US
AGEN
+1.46%
US
IBBQ
+1.65%
US
SBIO
+3.64%
StockTitan·
US
AGEN
+1.46%
US
IBBQ
+1.65%
US
SBIO
+3.64%

Agenus Buy Rating Reaffirmed as Late-Stage Strategy Advances; $23 Price Target Maintained

Tip Ranks·
US
AGEN
+1.46%
Tip Ranks·
US
AGEN
+1.46%

Agenus shares are trading lower. The company reported its Q1 financial results.

benzinga_article·
US
AGEN
+1.46%
US
IBBQ
+1.65%
US
LABU
+10.75%
benzinga_article·
US
AGEN
+1.46%
US
IBBQ
+1.65%
US
LABU
+10.75%

Agenus | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 33.7 M

Earnings Watch·
US
AGEN
+1.46%
Earnings Watch·
US
AGEN
+1.46%

Agenus Reports First Quarter 2026 Financial Results and Highlights BOT+BAL Execution Across Global Access and Phase 3 Development | AGEN Stock News

StockTitan·
US
AGEN
+1.46%
US
SBIO
+3.64%
US
PBE
+1.16%
StockTitan·
US
AGEN
+1.46%
US
SBIO
+3.64%
US
PBE
+1.16%

Agenus Q1 2026 Earnings Preview

businessinsider·
US
AGEN
+1.46%
US
FBT
+1.40%
US
PBE
+1.16%
businessinsider·
US
AGEN
+1.46%
US
FBT
+1.40%
US
PBE
+1.16%

Disrupting Scientific Friction: How Ome Ogbru Uses AI to Free Real Science

Unusual Whales·
US
AGEN
+1.46%
SH
CS精准医
+0.59%
US
INGN
-2.79%
Unusual Whales·
US
AGEN
+1.46%
SH
CS精准医
+0.59%
US
INGN
-2.79%

Agenus (AGEN) Expected to Announce Earnings on Monday

Market Beat·
US
AGEN
+1.46%
US
IBB
+1.75%
US
SBIO
+3.64%
Market Beat·
US
AGEN
+1.46%
US
IBB
+1.75%
US
SBIO
+3.64%
© 2026 Longbridge｜Disclaimer